Lung Cancer | Tumor

CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.

FDA Grants Accelerated Approval to Enhertu for Subgroup of Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

August 11th 2022

The FDA’s approval of Enhertu marks the first approval of a drug for patients with HER2-mutant unresectable or metastatic non-small cell lung cancer.

FDA Grants Tabrecta a Regular Approval for Certain Patients With Lung Cancer

August 11th 2022

The FDA approved Tabrecta for patients with non-small cell lung cancer who have a mutation that led to MET exon 14 skipping.

Two-Drug Combo Bests Chemotherapy in Front-Line Lung Cancer Treatment

August 10th 2022

Imfinzi plus tremelimumab led to better overall survival outcomes compared to standard chemotherapy in patients with metastatic non-small cell lung cancer.

EGFR C797X Mutation May Lead to Tagrisso Resistance in Patients With Lung Cancer

August 9th 2022

According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer.

Sugemalimab Demonstrates Improved Progression-Free Survival in Some Patients with Non-Small Cell Lung Cancer

August 9th 2022

Sugemalimab demonstrated safe and efficacious results when given after concurrent chemoradiation therapy or short-course chemoradiation therapy for patients with lung cancer.

Onivyde Fails to Improve Survival Over Chemotherapy in Second-Line Small Cell Lung Cancer

August 5th 2022

Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line treatment, according to findings from a primary analysis of the phase 3 RESILIENT trial.

Injectable Tecentriq Is Efficacious, Reduces Treatment Time for Lung Cancer

August 2nd 2022

Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.

5 Lung Cancer-Related Stories to Commemorate World Lung Cancer Day

August 1st 2022

In honor of World Lung Cancer Day, CURE® compiled the five most-read lung cancer-related news items from 2022 that patients may have missed.

Educated Patient® Lung Cancer Summit Looking Ahead Panel: June 25, 2022

July 29th 2022

Watch Dr. Ravi Salgia, Dr. Erminia Massarelli, Dr. Jyoti Malhotra and Daniel Saez answer questions about advancements in lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Advancements in Advanced-Stage Non-Small Cell Lung Cancer Presentation: June 25, 2022

July 28th 2022

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Advancements in Early-Stage Non-Small Cell Lung Cancer Presentation: June 25, 2022

July 27th 2022

Watch Dr. Erminia Massarelli, from City of Hope, discuss advancements in early-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Advancements in Small Cell Lung Cancer Presentation: June 25, 2022

July 26th 2022

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Overcoming Barriers to Receiving Biomarker Testing Panel: June 25, 2022

July 25th 2022

Watch Nikki Martin, Dr. Ying-Chun Lo and Dr. Hossein Borghaei discuss overcoming barriers to receiving biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Targeted Treatment Panel: June 25, 2022

July 24th 2022

Watch Elisabeth King, Dr. Edward S. Kim and Terri Conneran answer questions about targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Targeted Therapies Presentation: June 25, 2022

July 23rd 2022

Watch Dr. Edward S. Kim, from City of Hope, discuss targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Biomarker Testing Presentation: June 25, 2022

July 22nd 2022

Watch Elisabeth King, from City of Hope, discuss biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Basics of the Disease Panel: June 25, 2022

July 21st 2022

Watch Dr. Farhad Mazdisnian, Dr. Terence Williams and Dr. Antoinette J. Wozniak answer questions about the basics of the disease during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Radiation Advances Presentation: June 25, 2022

July 20th 2022

Watch Dr. Terrance M. Williams, from City of Hope, discuss radiation advances during the CURE Educated Patient Lung Cancer Summit.

Educated Patient® Lung Cancer Summit Staging Presentation: June 25, 2022

July 19th 2022

Watch Dr. Farhard Mazdisnian, from City of Hope, discuss diagnosing early, locally advanced and metastatic disease, during the CURE Educated Patient Lung Cancer Summit.

Cosela May Decrease Chemo-Related Blood Complications During Lung Cancer Treatment

July 18th 2022

Cosela tended to decrease myelosuppressive events — when the bone marrow is not working sufficiently to produce blood cells and platelets — in patients receiving chemotherapy for extensive-stage small cell lung cancer.

Study Launches to Investigate Effectiveness of Potential First-in-Class Lung Cancer Drug

July 11th 2022

The first patient was dosed in a phase 2 trial studying the efficacy of sapanisertib in patients with NRF2-mutant relapsed/refractory lung cancer.

Using Effective Cancer Therapies Earlier — Does It Always Work?

June 26th 2022

The stories in this issue of CURE illustrate how patients with cancer have become partners in therapeutic advances.

Novel Drug-Tecentriq Combo to Be Studied in Non-Small Cell Lung Cancer

June 17th 2022

A phase 2a trial is kicking off to study frontline GB1211 with the immunotherapy agent Tecentriq in patients with advanced or metastatic non-small cell lung cancer.

A Paradigm Shift in the Treatment of Early-Stage Lung Cancer May Be Leading to More Cures

June 16th 2022

Instead of waiting until the disease has progressed, researchers have begun analyzing the effects of using immunotherapy before or after surgery in patients with early-stage lung cancer. The results, according to experts, may be transformative for patients.

Durable Responses Continue with Keytruda Plus Chemoradiation in Previously Untreated Non-Small Cell Lung Cancer

June 8th 2022

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

Exkivity Delivers Minimal Benefit to Patients with Non-Small Cell Lung Cancer and Brain Metastases

June 8th 2022

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer

June 6th 2022

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer

June 6th 2022

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset

June 4th 2022

Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

Unmet Needs in the Management of EGFR Exon 20–Positive NSCLC

May 27th 2022

Before closing out their discussion on treatment for EGFR Exon 20–Positive NSCLC, experts discuss prominent unmet needs in this setting.

NEXT PAGE
PREVIOUS PAGE